Cardiogen (AEDR Tetrapeptide) — Cardiac Peptide Bioregulator Research Overview

Cardiogen (AEDR tetrapeptide; Ala-Glu-Asp-Arg; MW ~489 Da; C₁₈H₃₁N₇O₉) is a member of the Khavinson group's cytomedine class — short oligopeptides (di-, tri-, and tetrapeptides) derived from organ-specific tissue isolates and proposed to act as epigenetic regulators of gene expression in a tissue-preferential manner. The theoretical framework: tissue-derived short peptides bind to double-stranded DNA at complementary histone-associated promoter regions, modulating chromatin structure and gene transcription, with tissue preference arising from the peptide's composition matching regulatory sequences enriched in the cognate tissue. For Cardiogen, the AEDR sequence is proposed to preferentially modulate gene expression in cardiomyocytes and cardiac tissue, though the precise molecular targets and receptor mechanisms remain subject to ongoing research debate. Published Khavinson group work on Cardiogen spans cardiac aging models, post-ischemia cardiomyocyte studies, oxidative-stress protection, and chronic cardiac insufficiency animal models (primarily in rats/mice).

Pre-clinical cardiac research with Cardiogen has examined its effects in models of: cardiac ischemia-reperfusion injury (cardiomyocyte survival rates, enzyme-release markers), age-related cardiac decline (myocardial protein synthesis rates, cardiomyocyte morphology in aging rodents), oxidative stress protection (ROS-scavenging capacity, mitochondrial membrane potential preservation), and cardiac insufficiency models (ejection fraction parameters, collagen deposition, fibrosis markers in chronic models). The Khavinson group's published work reports dose-dependent cardioprotective effects in these models, with Cardiogen showing reduced histological cardiac damage vs controls and preservation of cardiomyocyte ultrastructure under stress conditions. As with other Khavinson cytomedines, the published evidence base is concentrated in the Khavinson group's own publications with limited independent replication; the mechanistic pathway from AEDR peptide → gene-level modulation → cardiac protection is proposed but not established by consensus-level receptor pharmacology. The compound is of interest to researchers studying short-peptide bioregulators, cardiac aging, and the cytomedine class more broadly.

Cardiogen belongs to the same Khavinson cytomedine series as Pinealon (EDR tripeptide, pineal/brain bioregulator), Vilon (Lys-Glu KE dipeptide, thymus/immune bioregulator), and Cortagen (AEDP tetrapeptide, brain cortex bioregulator). The series is characterized by: extreme simplicity (2–4 amino acids), proposed tissue-specific gene-level activity, high stability under physiological conditions (short sequences resist proteolysis compared to larger peptides), and Russian Institute origins. All four cytomedines in the series are represented in the DMV Research compound library, enabling researchers to study the cytomedine class systematically across cardiac, neural, thymic, and cortical tissue models in parallel experimental designs. DMV Research supplies Cardiogen (AEDR) as a lyophilized research compound with per-batch Certificate of Analysis confirming identity by mass spectrometry and purity ≥99% by HPLC.